COGNITIVE IMPAIRMENT AND DEMENTIA IN PARKINSON'S DISEASE
A. Kondybayeva,
S. Kamenova,
K. Kuzhybayeva,
D. Ospanbekova,
S. Kenebayeva,
K. Saduakasova,
M. Zhanuzakov https://doi.org/10.64854/2790-1289-2025-49-3-01
Abstract
Cognitive impairment is one of the most frequent and disabling non-motor manifestations of Parkinson's disease. It significantly reduces patients' quality of life, increases caregiver burden, and contributes to loss of independence. Early identification of cognitive decline is crucial for timely intervention and prevention of dementia progression.
The purpose of the study. To determine the prevalence of cognitive impairment and identify predictors of progression to dementia among patients with Parkinson's disease.
Material and Methods. A total of 106 patients with PD were examined and followed in outpatient clinics in Almaty. The diagnosis of Parkinson's disease was confirmed according to international criteria. Cognitive status was assessed using the Mini-Mental State Examination and Montreal Cognitive Assessment. Disease severity was evaluated using the Hoehn and Yahr scale and the Schwab and England Activities of Daily Living Scale. Demographic and clinical parameters, including age, education level, disease duration, and motor subtype, were analyzed.
Results. Mild cognitive impairment was identified in 26.4% of patients, dementia in 34.9%, and no cognitive impairment in 38.7%. More pronounced cognitive decline was more common among older patients, those with lower educational attainment, disease duration over 10 years, and the akinetic-rigid subtype of Parkinson's disease. Regression analysis revealed the key predictors of dementia: disease onset after age 60, duration exceeding 19 years, low education level, and severe motor deficit.
Conclusion. Cognitive impairment is common among Parkinson's disease patients and tends to progress with disease duration and severity. Early detection and systematic monitoring of cognitive functions are essential for implementing preventive measures, slowing dementia progression, and improving the quality of life of individuals with Parkinson's disease.
About the Authors
A. KondybayevaKazakhstan
PhD, Head of the Scientific and Educational Center of Neurology and Applied Neuroscience, Asfendiyarov Kazakh National Medical University,
Almaty
S. Kamenova
Kazakhstan
Doctor of Medical Sciences, Professor of the Department of Family Medicine-2, Asfendiyarov Kazakh National Medical University,
Almaty
K. Kuzhybayeva
Kazakhstan
Candidate of Medical Sciences, Associate Professor, Head of the Department for Autoimmune, Degenerative, Demyelinating and Orphan Diseases of the Nervous System, Public Health Department of Almaty
D. Ospanbekova
Kazakhstan
Master of Medicine, Researcher at the Scientific and Educational Center of Neurology and Applied Neuroscience, Asfendiyarov Kazakh National Medical University,
Almaty
S. Kenebayeva
Kazakhstan
Director of the State Enterprise «Primary Health Care Center of Medeu District» of the Public Health Department of Almaty, Kazakhstan
K. Saduakasova
Kazakhstan
Candidate of Medical Sciences, Associate Professor, Department of Family Medicine, Al-Farabi Kazakh National University,
Almaty
M. Zhanuzakov
Kazakhstan
Doctor of Medical Sciences, Professor, Department of Family Medicine, Al-Farabi Kazakh National University,
Almaty
References
1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al.. Parkinson disease. Nat Rev Dis Primers. (2017) 3:17013. 10.1038/nrdp.2017.13
2. GBD Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. (2017) 16:877–97. 10.1016/S1474-4422(17)30299-5
3. GBD Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. (2019) 18:459–80. 10.1016/S1474-4422(18)30499-X
4. GBD Disease Incidence, Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1789–858. 10.1016/S0140-6736(18)32279-7
5. Kalia L. V., Lang A. E. (2015). Parkinson's disease. Lancet 386, 896–912. 10.1016/S0140-6736(14)61393-3
6. Hely A, Morris JG, Reid WG, Traffificante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–199. doi:10.1002/mds.20324
7. Santangelo G, Vitale C, Picillo M, et al. Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219–1226. doi:10.1016/j.parkreldis.2015.08.024
8. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264. doi:10.1136/jnnp-2013-305277
9. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., Burn D., Barone P., Pagonabarraga J., Allcock L., Santangelo G., Foltynie T., Janvin C., Larsen J. P., Barker R. A., Emre M. (2010). Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75, 1062–1069 10.1212/WNL.0b013e3181f39d0e
10. Barone P., Aarsland D., Burn D., Emre M., Kulisevsky J., Weintraub D. (2011). Cognitive impairment in nondemented Parkinson’s disease. Mov. Disord. 26, 2483–2495 10.1002/mds.23919
11. Litvan, I.; Goldman, J.G.; Troster, A.I.; Schmand, B.A.; Weintraub, D.; Petersen, R.C.; Mollenhauer, B.; Adler, C.H.; Marder, K.; Williams-Gray, C.H.; et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 2012, 27, 349–356.
12. Fengler, S. et al. Cognitive changes in prodromal Parkinson’s disease: a review. Mov. Disord. 32, 1655–1666 (2017).
13. Hely M. A., Reid W. G., Adena M. A., Halliday G. M., Morris J. G. (2008). The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844 10.1002/mds.21956
14. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–231. doi:10.1038/nrneurol.2017.27
15. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord. 2011;26(4):629–636. doi:10.1002/mds.23592
16. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708–1713. doi:10.1212/01.WNL.0000036610.36834.E0
17. Pedersen, K. F., Larsen, J. P., Tysnes, O. B. & Alves, G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88, 767–774 (2017). One of the first studies based on an incidence cohort, reporting the natural course of PD-MCI, diagnosed using standardized criteria over time.
18. Lawson, R. A. et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2017,88, 648– 652
19. Domellof, M. E., Ekman, U., Forsgren, L. & Elgh, E. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol. Scand. 2015,132, 79–88.
20. Weintraub, D. et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov. Disord. 2015, 30, 919–927.
21. Roberts, R. & Knopman, D. S. Classification and epidemiology of MCI. Clin. Geriatr. Med. 29, 753–772 (2013).
22. Pedersen, K. F., Larsen, J. P., Tysnes, O. B. & Alves, G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88, 767–774 (2017).
23. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. doi:10.1002/mds.21507
24. Leggio L., Vivarelli S. et al. microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches // International Journal of Molecular Sciences. – 2017. – Vol. 18(12). – P. 2698-12698-30.
25. Sauerbier A., Jitkritsadakul O., Titova N. et al. Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson’s Disease in Selected Asian Populations // Neuroepidemiology. – 2017. – Vo. 49. – P. 1-17.
26. Braak H., Del Tredici K., Bratzke H et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) // J Neurol. - 2002. - Vol. 249, Suppl 3. - P. 1-5.
27. Anna B. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiology of Aging. 2005;26:891–898.
28. Akanova A.A. Epidemiological and clinical and genetic features of Parkinson's disease in patients of Kazakhstan on the example of the city of Almaty: Dissertation paper for PhD: Shifr. - Almaty, 2016. - 134 p.
29. Aralbaeva A.D. Clinical and genetic features of Parkinson's disease in the Republic of Kazakhstan : Dissertation paper for PhD: Shifr. - Almaty, 2022. - 134 p.
30. S.Kamenova A. Aralbayeva A . Kondybayeva A . Akimniyazova A . Pyrkova A. Ivashchenko Evolutionary changes in the interaction of miRNA with mRNA of candidate genes for Parkinson's disease. Frontiers in Genetics. March 2021 Vol.12
31. Akanova A., Kamenova S., Yeshmanova A., Beltenova A., et al., The evaluation of cognitive skills and the quality of life between Parkinson Disease patients and healthy aged people above 60 years old. Advances in Gerontology.2015, 28 (4), 741-748
32. Kamenova S.U., Aralbayeva A.D., Iskakova S.A., Kondybayeva A.M., Kuzhybayeva K.K., D. Truong. Non-motor visual disorders in Kazakhtan patients with Parkinson's disease. Journal of Interdisciplinary Approaches to Medicine Vol.2 N1(2021)P3-12. https://doi.org/10.26577/IAM.2021.v2.i2.07
33. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
34. Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement. 2012;8(6):463–469.
35. Auyeung M, Tsoi TH, Mok V, et al. Ten-year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry. 2012;83(6):607–611.
36. Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81(4):346–352.
37. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;82(4):308–316.
38. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
39. Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement. 2012;8(6):463–469.
40. Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatr Psychiatry Neurol. 2014;27(4):276–281.
41. Hong JY, Sunwoo MK, Chung SJ, et al. Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson’s disease. Neurobiol Aging. 2014;35(7):1739–1743.
Review
For citations:
Kondybayeva A., Kamenova S., Kuzhybayeva K., Ospanbekova D., Kenebayeva S., Saduakasova K., Zhanuzakov M. COGNITIVE IMPAIRMENT AND DEMENTIA IN PARKINSON'S DISEASE. Actual Problems of Theoretical and Clinical Medicine. 2025;(3). https://doi.org/10.64854/2790-1289-2025-49-3-01
